| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Bravo, L, et al.
(author)
-
- 2021
-
swepub:Mat__t
|
|
| 5. |
- Tabiri, S, et al.
(author)
-
- 2021
-
swepub:Mat__t
|
|
| 6. |
- Glasbey, JC, et al.
(author)
-
- 2021
-
swepub:Mat__t
|
|
| 7. |
|
|
| 8. |
- Khatri, C, et al.
(author)
-
Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study
- 2021
-
In: BMJ open. - : BMJ. - 2044-6055. ; 11:11, s. e050830-
-
Journal article (peer-reviewed)abstract
- Studies have demonstrated high rates of mortality in people with proximal femoral fracture and SARS-CoV-2, but there is limited published data on the factors that influence mortality for clinicians to make informed treatment decisions. This study aims to report the 30-day mortality associated with perioperative infection of patients undergoing surgery for proximal femoral fractures and to examine the factors that influence mortality in a multivariate analysis.SettingProspective, international, multicentre, observational cohort study.ParticipantsPatients undergoing any operation for a proximal femoral fracture from 1 February to 30 April 2020 and with perioperative SARS-CoV-2 infection (either 7 days prior or 30-day postoperative).Primary outcome30-day mortality. Multivariate modelling was performed to identify factors associated with 30-day mortality.ResultsThis study reports included 1063 patients from 174 hospitals in 19 countries. Overall 30-day mortality was 29.4% (313/1063). In an adjusted model, 30-day mortality was associated with male gender (OR 2.29, 95% CI 1.68 to 3.13, p<0.001), age >80 years (OR 1.60, 95% CI 1.1 to 2.31, p=0.013), preoperative diagnosis of dementia (OR 1.57, 95% CI 1.15 to 2.16, p=0.005), kidney disease (OR 1.73, 95% CI 1.18 to 2.55, p=0.005) and congestive heart failure (OR 1.62, 95% CI 1.06 to 2.48, p=0.025). Mortality at 30 days was lower in patients with a preoperative diagnosis of SARS-CoV-2 (OR 0.6, 95% CI 0.6 (0.42 to 0.85), p=0.004). There was no difference in mortality in patients with an increase to delay in surgery (p=0.220) or type of anaesthetic given (p=0.787).ConclusionsPatients undergoing surgery for a proximal femoral fracture with a perioperative infection of SARS-CoV-2 have a high rate of mortality. This study would support the need for providing these patients with individualised medical and anaesthetic care, including medical optimisation before theatre. Careful preoperative counselling is needed for those with a proximal femoral fracture and SARS-CoV-2, especially those in the highest risk groups.Trial registration numberNCT04323644
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
- Allentoft, M. E., et al.
(author)
-
Population genomics of Bronze Age Eurasia
- 2015
-
In: Nature. - : Springer Science and Business Media LLC. - 0028-0836 .- 1476-4687. ; 522:7555
-
Journal article (peer-reviewed)abstract
- The Bronze Age of Eurasia (around 3000-1000 BC) was a period of major cultural changes. However, there is debate about whether these changes resulted from the circulation of ideas or from human migrations, potentially also facilitating the spread of languages and certain phenotypic traits. We investigated this by using new, improved methods to sequence low-coverage genomes from 101 ancient humans from across Eurasia. We show that the Bronze Age was a highly dynamic period involving large-scale population migrations and replacements, responsible for shaping major parts of present-day demographic structure in both Europe and Asia. Our findings are consistent with the hypothesized spread of Indo-European languages during the Early Bronze Age. We also demonstrate that light skin pigmentation in Europeans was already present at high frequency in the Bronze Age, but not lactose tolerance, indicating a more recent onset of positive selection on lactose tolerance than previously thought.
|
|
| 13. |
- Archilli, F., et al.
(author)
-
Search for a vector gauge boson in phi meson decays with the KLOE detector KLOE-2 Collaboration
- 2012
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 706:4-5, s. 251-255
-
Journal article (peer-reviewed)abstract
- The existence of a light dark force mediator has been tested with the KLOE detector at DA Phi NE. This particle, called U. is searched for using the decay chain phi -> eta U, eta -> pi(+)pi(-)pi(0), U -> e(+)e(-). No evidence is found in 1.5 fb(-1) of data. The resulting exclusion plot covers the mass range 5 < M-U < 470 MeV, setting an upper limit on the ratio between the U boson coupling constant and the One structure constant, alpha'/alpha, of <= 2 x 10(-5) at 90% C.L. for 50 < M-U < 420 MeV.
|
|
| 14. |
- Babusci, D., et al.
(author)
-
A new limit on the CP violating decay K-S -> 3 pi(0) with the KLOE experiment
- 2013
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 723:1-3, s. 54-60
-
Journal article (peer-reviewed)abstract
- We have carried out a new direct search for the CP violating decay K-S -> 3 pi(0) with 1.7 fb(-1) of e(+)e(-) collisions collected by the KLOE detector at the Phi-factory DA Phi NE. We have searched for this decay in a sample of about 5.9 x 10(8) KSKL events tagging the K-S by means of the K-L interaction in the calorimeter and requiring six prompt photons. With respect to our previous search, the analysis has been improved by increasing of a factor four the tagged sample and by a more effective background rejection of fake K-S tags and spurious clusters. We find no candidates in data and simulated background samples, while we expect 0.12 standard model events. Normalizing to the number of K-S -> 2 pi(0) events in the same sample, we set the upper limit on BR(K-S -> 3 pi(0)) <= 2.6 x 10(-8) at 90% C.L., five times lower than the previous limit. We also set the upper limit on the eta(000) parameter, vertical bar eta(000)vertical bar <= 0.0088 at 90% C.L., improving by a factor two the latest direct measurement. (c) 2013 Elsevier B.V. All rights reserved.
|
|
| 15. |
- Babusci, D., et al.
(author)
-
Limit on the production of a light vector gauge boson in phi meson decays with the KLOE detector
- 2013
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 720:1-3, s. 111-115
-
Journal article (peer-reviewed)abstract
- We present a new limit on the production of a light dark-force mediator with the KLOE detector at DA Phi NE. This boson, called U, has been searched for in the decay phi -> eta U, U -> e(+)e(-), analyzing the. decay eta -> pi(0)pi(0)pi(0) in a data sample of 1.7 fb(-1). No structures are observed in the e(+)e(-) invariant mass distribution over the background. This search is combined with a previous result obtained from the decay eta -> pi(+)pi(-)pi(0), increasing the sensitivity. We set an upper limit at 90% C.L. on the ratio between the U boson coupling constant and the fine structure constant of alpha'/alpha < 1.7 x 10(-5) for 30 < M-U < 400 MeV and alpha'/alpha <= 8 x 10(-6) for the sub-region 50 < M-U <210 MeV. This result assumes the Vector Meson Dominance expectations for the phi eta gamma* transition form factor. The dependence of this limit on the transition form factor has also been studied.
|
|
| 16. |
- Babusci, D., et al.
(author)
-
Measurement of eta meson production in gamma gamma interactions and Gamma(eta -> gamma gamma) with the KLOE detector
- 2013
-
In: Journal of High Energy Physics (JHEP). - 1126-6708 .- 1029-8479. ; :1, s. 119-
-
Journal article (peer-reviewed)abstract
- We present a measurement of eta meson production in photon-photon interactions produced by electron-positron beams colliding with root s = 1 GeV. The measurement is done with the KLOE detector at the phi-factory DA Phi NE with an integrated luminosity of 0.24 fb(-1). The e(+)e(-) -> e(+)e(-)eta cross section is measured without detecting the outgoing electron and positron, selecting the decays eta -> pi(+)pi(-)pi(0) and eta -> pi(0)pi(0)pi(0). The most relevant background is due to e(+)e(-) -> eta gamma when the monochromatic photon escapes detection. The cross section for this process is measured as sigma(e(+)e(-) -> eta gamma) = (856 +/- 8(stat) +/- 16(syst)) pb. The combined result for the e(+)e(-) -> e(+)e(-)eta cross section is sigma(e(+)e(-) -> e(+)e(-)eta) = (32.72 +/- 1.27(stat) +/- 0.70(syst)) pb. From this we derive the partial width Gamma(eta -> gamma gamma) = (520 +/- 20(stat) +/- 13(syst)) eV. This is in agreement with the world average and is the most precise measurement to date.
|
|
| 17. |
- Babusci, D., et al.
(author)
-
Measurement of Γ(η→π+π-γ)/Γ(η→π+π-π0) with the KLOE detector
- 2013
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 718:3, s. 910-914
-
Journal article (peer-reviewed)abstract
- The ratio Rη=Γ(η→π+π-γ)/Γ(η→π+π-π0) has been measured by analysing 22 million φ→ηγ decays collected by the KLOE experiment at DAΦNE, corresponding to an integrated luminosity of 558 pb-1. The η→π+π-γ proceeds both via the ρ resonant contribution, and possibly a non-resonant direct term, connected to the box anomaly. Our result, Rη=0.1856±0.0005stat±0.0028syst, points out a sizable contribution of the direct term to the total width. The di-pion invariant mass for the η→π+π-γ decay could be described in a model-independent approach in terms of a single free parameter, α. The determined value of the parameter α is α=(1.32±0.08stat-0.09syst+0.10±0.02theo) GeV-2.
|
|
| 18. |
- Babusci, D., et al.
(author)
-
Precision measurement of sigma (e(+)e(-) -> pi(+)pi(-)gamma)/sigma(e(+)e(-) ->mu(+)mu(-)gamma) and determination of the pi(+)pi(-) contribution to the muon anomaly with the KLOE detector
- 2013
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 720:4-5, s. 336-343
-
Journal article (peer-reviewed)abstract
- We have measured the ratio cr (e(+)e(-) -> pi(+)pi(-)gamma)/sigma(e(+)e(-) -> mu(+)mu(-)gamma), with the KLOE detector at DA Phi NE for a total integrated luminosity of similar to 240 pb(-1). From this ratio we obtain the cross section sigma (e(+)e(-) -> pi(+)pi(-)gamma). From the cross section we determine the pion form factor vertical bar F-pi vertical bar(2) and the two-pion contribution to the muon anomaly a(mu) for 0.592< M-pi pi < 0.975 GeV, Delta(pi pi) a(mu) = (385.1 +/- 1.1(stat) +/- 2.7(sys+theo)) x 10(-10). This result confirms the current discrepancy between the Standard Model calculation and the experimental measurement of the muon anomaly. (c) 2013 Elsevier B.V. All rights reserved.
|
|
| 19. |
- Babusci, D., et al.
(author)
-
Search for light vector boson production in e(+)e(-) -> mu(+)mu(-)gamma interactions with the KLOE experiment
- 2014
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 736, s. 459-464
-
Journal article (peer-reviewed)abstract
- We have searched for a light vector boson U, the possible carrier of a "dark force", with the KLOE detector at the DA Phi NE e(+)e(-) collider, motivated by astrophysical evidence for the presence of dark matter in the Universe. Using e(+)e(-) collisions collected with an integrated luminosity of 239.3 pb(-1), we look for a dimuon mass peak in the reaction e(+)e(-) -> mu(+)mu(-)gamma, corresponding to the decay U -> mu(+)mu(-). We find no evidence for a U vector boson signal. We set a 90% CL upper limit for the mixing parameter squared between the photon and the U boson of 1.6 x 10(-5) to 8.6 x 10(-7) for the mass region 520 < m(U) < 980 MeV.
|
|
| 20. |
- Babusci, D., et al.
(author)
-
Study of the Dalitz decay phi -> eta e(+)e(-) with the KLOE detector
- 2015
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 742, s. 1-6
-
Journal article (peer-reviewed)abstract
- We have studied the vector to pseudoscalar conversion decay phi -> eta e(+)e(-), with.. eta -> pi(0)pi(0)pi(0), with the KLOE detector at DA phi NE. The data set of 1.7 fb(-1) of e(+)e(-) collisions at root s similar to M-phi contains a clear conversion decay signal of similar to 31,000 events from which we measured a value of BR(phi -> eta e(+)e-) = (1.075 +/- 0.007 +/- 0.038) x 10(-4). The same sample is used to determine the transition form factor by a fit to the e(+)e(-) invariant mass spectrum, obtaining b(phi eta)=( 1.28 +/- 0.10(-0.08)(+0.09)) GeV-2, that improves by a factor of five the precision of the previous measurement and is in good agreement with VMD expectations.
|
|
| 21. |
- Babusci, D., et al.
(author)
-
Test of CPT and Lorentz symmetry in entangled neutral kaons with the KLOE experiment
- 2014
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 730, s. 89-94
-
Journal article (peer-reviewed)abstract
- Neutral kaon pairs produced in phi decays in anti-symmetric entangled state can be exploited to search for violation of CPT symmetry and Lorentz invariance. We present an analysis of the CP-violating process phi -> KSKL -> pi(+)pi(-)pi(+)pi(-) based on 1.7 fb(-1) of data collected by the KLOE experiment at the Frascati phi-factory DA Phi NE. The data are used to perform a Measurement of the CPT-violating parameters Delta a(mu) for neutral kaons in the context of the Standard Model Extension framework. The parameters measured in the reference frame of the fixed stars are: Delta a(0) = (-6.0 +/- 7.7(stat)+/- 3.1(syst)) X 10(-18) GeV, Delta a(x) = (0.9 +/- 1.5(stat)+/- 0.6(syst)) X 10(-18) GeV, Delta a(y) = (-2.0 +/- 1.5(stat)+/- 0.5(syst)) X 10(-18) GeV, Delta a(z) = (3.1 +/- 1.7(stat)+/- 0.5(syst)) X 10(-18) GeV. These are presently the most precise measurements in the quark sector of the Standard Model Extension. (C) 2014 The Authors. Published by Elsevier B.V.
|
|
| 22. |
- Babuscih, D., et al.
(author)
-
Measurement of the absolute branching ratio of the K+ -> pi(+) pi(-) pi(+) (gamma) decay with the KLOE detector
- 2014
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 738, s. 128-133
-
Journal article (peer-reviewed)abstract
- The absolute branching ratio of the K+ -> pi(+) pi(-) pi(+) (gamma) decay, inclusive of final-state radiation, has been measured using similar to 17 million tagged K+ mesons collected with the KLOE detector at DA Phi NE, the Frascati phi-factory. The result is: BR(K+ -> pi(+) pi(-) pi(+) (gamma)) = 0.05565 +/- 0.00031(stat) +/- 0.00025(syst) a factor similar or equal to 5 more precise with respect to the previous result. This work completes the program of precision measurements of the dominant kaon branching ratios at KLOE.
|
|
| 23. |
|
|
| 24. |
- Ferrari, S, et al.
(author)
-
Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups
- 2005
-
In: Journal of Clinical Oncology. - 1527-7755. ; 23:34, s. 8845-8852
-
Journal article (peer-reviewed)abstract
- Purpose To explore the effect of high-dose ifosfamide in first-line treatment for patients <= 40 years of age with nonmetastatic osteosarcoma of the extremity. Patients and Methods From March 1997 to September 2000, 182 patients were evaluated. Primary treatment consisted of two blocks of high-dose ifosfamide (15 g/m(2)), methotrexate (12 g/m(2)), cisplatin (120 mg/m(2)), and doxorubicin (75 mg/m(2)). Postoperatively, patients received two cycles of doxorubicin (go mg/m(2)), and three cycles each of high-dose ifosfamide, methotrexate, and cisplatin (120 to 150 mg/m(2)). Granulocyte colony-stimulating factor support was mandatory after the high-dose ifosfamide/cisplatin/doxorubicin combination. Results No disease progression was recorded during primary chemotherapy, 164 patients (92%) underwent limb-salvage surgery, four patients (2%) underwent rotation plasty, and 11 patients (6%) had limbs amputated. Three (1.6%) patients died as a result of treatment-related toxicity, and one died as a result of pulmonary embolism after pathologic fracture. Grade 4 neutropenia and thrombocytopenia followed 52% and 31% of all courses, respectively, and mild to severe nephrotoxicity was recorded in 19 patients (10%). The median received dose-intensity compared with protocol was 0.82. With a median follow-up of 55 months, the 5-year probability of event-free survival was 64% (95% CI 57% to 71%) and overall survival was 77% (95% CI 67% to 81%), whereas seven patients (4%) experienced local recurrence. Conclusion The addition of high-dose ifosfamide to methotrexate, cisplatin, and doxorubicin in the preoperative phase is feasible, but with major renal and hematologic toxicities, and survival rates similar to those obtained with four-drug regimens using standard-dose ifosfamide. Italian Sarcoma Group/Scandinavian Sarcoma Group study I showed that in a multicenter setting, more than 90% of patients with osteosarcoma of the extremity can undergo conservative surgery.
|
|
| 25. |
|
|
| 26. |
- Beisner, Beatrix E., et al.
(author)
-
The role of environmental and spatial processes in structuring lake communities from bacteria to fish
- 2006
-
In: Ecology. - 0012-9658 .- 1939-9170. ; 87:12, s. 2985-2991
-
Journal article (peer-reviewed)abstract
- We assessed the relative roles of local environmental conditions and dispersal on community structure in a landscape of lakes for the major trophic groups. We use taxonomic presence–absence and abundance data for bacteria, phytoplankton, zooplankton, and fish from 18 lakes in southern Quebec, Canada. The question of interest was whether communities composed of organisms with more limited dispersal abilities, because of size and life history (zooplankton and fish) would show a different effect of lake distribution than communities composed of good dispersers (bacteria and phytoplankton). We examine the variation in structure attributable to local environmental (i.e., lake chemical and physical variables) vs. dispersal predictors (i.e., overland and watercourse distances between lakes) using variation partitioning techniques. Overall, we show that less motile species (crustacean zooplankton and fish) are better predicted by spatial factors than by local environmental ones. Furthermore, we show that for zooplankton abundances, both overland and watercourse dispersal pathways are equally strong, though they may select for different components of the community, while for fish, only watercourses are relevant dispersal pathways. These results suggest that crustacean zooplankton and fish are more constrained by dispersal and therefore more likely to operate as a metacommunity than are bacteria and phytoplankton within this studied landscape.
|
|
| 27. |
|
|
| 28. |
- Ferrari, Stefano, et al.
(author)
-
EURO-B.O.S.S. : A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma
- 2018
-
In: Tumori. - : SAGE Publications. - 0300-8916 .- 2038-2529. ; 104:1, s. 30-36
-
Journal article (peer-reviewed)abstract
- INTRODUCTION: The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective international study for patients 41-65 years old with high-grade bone sarcoma treated with an intensive chemotherapy regimen derived from protocols for younger patients with high-grade skeletal osteosarcoma.METHODS: Chemotherapy based on doxorubicin, cisplatin, ifosfamide, and methotrexate was suggested, but patients treated with other regimens at the investigators' choice were also eligible for the study.RESULTS: The present report focuses on the subgroup of 218 patients with primary high-grade osteosarcoma. With a median follow-up of 47 months, the 5-year probability of overall survival (OS) was 66% in patients with localized disease and 22% in case of synchronous metastases. The 5-year OS in patients with localized disease was 29% in pelvic tumors, and 70% and 73% for extremity or craniofacial locations, respectively. In primary chemotherapy, tumor necrosis ≥90% was reported in 21% of the patients. There were no toxic deaths; however, hematological toxicity was considerable with 32% of patients experiencing 1 or more episodes of neutropenic fever. The incidence of nephrotoxicity and neurotoxicity (mainly peripheral) was 28% and 24%, respectively. After methotrexate, 23% of patients experienced delayed excretion, in 4 cases with nephrotoxicity.CONCLUSIONS: In patients over 40 years of age with primary high-grade osteosarcoma, an aggressive approach with chemotherapy and surgery can offer the probability of survival similar to that achieved in younger patients. Chemotherapy-related toxicity is significant and generally higher than that reported in younger cohorts of osteosarcoma patients treated with more intensive regimens.
|
|
| 29. |
|
|
| 30. |
- Lazar, Tamas, et al.
(author)
-
PED in 2021 : A major update of the protein ensemble database for intrinsically disordered proteins
- 2021
-
In: Nucleic Acids Research. - : Oxford University Press (OUP). - 0305-1048 .- 1362-4962. ; 49:D1, s. 404-411
-
Journal article (peer-reviewed)abstract
- The Protein Ensemble Database (PED) (https://proteinensemble.org), which holds structural ensembles of intrinsically disordered proteins (IDPs), has been significantly updated and upgraded since its last release in 2016. The new version, PED 4.0, has been completely redesigned and reimplemented with cutting-edge technology and now holds about six times more data (162 versus 24 entries and 242 versus 60 structural ensembles) and a broader representation of state of the art ensemble generation methods than the previous version. The database has a completely renewed graphical interface with an interactive feature viewer for region-based annotations, and provides a series of descriptors of the qualitative and quantitative properties of the ensembles. High quality of the data is guaranteed by a new submission process, which combines both automatic and manual evaluation steps. A team of biocurators integrate structured metadata describing the ensemble generation methodology, experimental constraints and conditions. A new search engine allows the user to build advanced queries and search all entry fields including cross-references to IDP-related resources such as DisProt, MobiDB, BMRB and SASBDB. We expect that the renewed PED will be useful for researchers interested in the atomic-level understanding of IDP function, and promote the rational, structure-based design of IDP-targeting drugs.
|
|
| 31. |
- Persson Berg, Linn, 1984, et al.
(author)
-
Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment
- 2022
-
In: Bmj Neurology Open. - : BMJ. - 2632-6140. ; 4:2
-
Journal article (peer-reviewed)abstract
- Background Patients with multiple sclerosis (MS) demonstrate higher seroprevalence of Epstein-Barr virus (EBV) and increased anti-EBV IgG levels in serum compared with healthy controls. Intrathecal antibody production to measles virus (MeV) is a common finding in patients with MS. Objective To measure serum IgG reactivity to EBV glycoprotein 350 (gp350) and MeV nucleocapsid protein (N-CORE) in patients with MS and healthy controls and to determine if reactivity changed in patients during interferon beta (IFN beta) and/or natalizumab (NAT) treatment. A secondary aim was to determine the seroprevalence of EBV in patients and controls. Methods Patients with MS (n=728) were included from the Swedish pharmacovigilance study for NAT. Paired serum samples from 714 patients drawn before and during NAT treatment and paired samples from 170 patients during prior IFN beta treatment were analysed. In total, 156 patients were included in both groups. Samples from 144 matched blood donors served as controls. Indirect ELISA was applied using recombinant EBVgp350 and MeV N-CORE as antigens. EBVgp350 IgG seronegative samples were also analysed using EBV nuclear antigen 1 and viral capsid antigen (VCA). Results Patients with MS showed higher serum levels of anti-EBVgp350 and anti-MeV N-CORE IgG compared with controls. During NAT treatment, the levels of anti-EBVgp350 and anti-MeV N-CORE IgG declined, compared with the relatively stable levels noted during prior IFN beta treatment. Ten patients failed to demonstrate anti-EBVgp350 IgG but did show detectable anti-VCA IgG, indicating EBV seropositivity. In contrast, 10/144 controls were EBV seronegative. Conclusions Treatment with NAT, which is considered a selective immunosuppressive agent with a compartmentalised effect on the central nervous system, appeared to be associated with a moderate decrease in circulating IgG levels to EBVgp350 and MeV N-CORE. All patients with MS were EBV IgG seropositive, supporting the potential role of EBV in the pathogenesis of MS.
|
|
